Advanced Development of OXOS X3, a Point-of-Care Diagnostic X-Ray Imaging System for Detection of Fracture and other Trauma

The U.S. Department of Health and Human Services awarded a multi‑year, high‑value contract to OXOS Medical, Inc. to design, develop, and secure FDA clearance for the OXOS X3 – an ultra‑portable, high‑output radiography and fluoroscopy system intended for rapid deployment in mass‑casualty incidents. The system must weigh ≤ 25 lb, deliver up to 100 kV/15 mA, and function as a threat‑agnostic medical countermeasure, enhancing point‑of‑need diagnostic capability across emergency departments, field hospitals, and triage sites. The contract totals roughly $49 million and includes base award plus all option periods, reflecting a substantial, multi‑year commitment to advance trauma response technology. • Scope: Design, prototype, test, and obtain FDA clearance for the OXOS X3 portable X‑ray/fluoroscopy system. • Technical requirements: ≤ 25 lb, up to 100 kV / 15 mA, capable of operating in diverse MCM scenarios (nuclear, blast, trauma surge). • Funding: Approximately $48.9 million covering base award and all options, funded by HHS/ASPR for medical countermeasure development.